RF Acquisition Corp II Ordinary Shares
RFAI
NASDAQ Global Market11.07
USD
+0.01
- -
CIK
0002012807
ISIN
KYG753891095
CUSIP
G75389109
Return %
Stock
S&P500
1Y
4.63
18.21
3Y
10.26
64.38
5Y
10.26
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Tse Meng Ng
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- No. 05-07, 111 Somerset Singapore CE Singapore
- IPO Date
- Jul 5, 2024
- CIK
- 0002012807
- Website
- rfacquisitioncorp.com
- Similar Companies
- Business
- RF Acquisition Corp II operates as a blank check company incorporated in 2024 and headquartered in Singapore. The company primarily focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combinations with one or more target businesses. Its search centers on companies in the technology sector, specifically involving artificial intelligence, quantum computing, and biotechnology in Asia. The company does not have significant operations or direct product manufacturing but aims to acquire businesses that manufacture or provide advanced technology solutions. A key recent development is RF Acquisition Corp II's business combination agreement with Nanyang Biologics Pte. Ltd., a Singapore-based AI drug discovery pioneer. This reverse merger, valued at approximately $1.5 billion, positions Nanyang Biologics as a wholly-owned subsidiary of the combined entity, marking a major strategic expansion into biotech and AI drug discovery markets. The transaction reflects RF Acquisition Corp II's strategic shift from a blank check entity to an operating public company with substantial involvement in high-growth technology sectors. RF Acquisition Corp II was listed on NASDAQ in May 2024 and continues to operate from Singapore with a market capitalization in the range of $130 to $160 million as of late 2025. Its leadership includes chairman and CEO Tse Meng Ng, who brings expertise in wealth management and financial services. The company targets Asian markets for acquisition, supporting growth in advanced technology fields, notably AI and biotech. In summary, RF Acquisition Corp II provides financial and strategic platforms to acquire and operate technology-focused businesses, recently transitioning through a significant merger with Nanyang Biologics that expands its footprint in AI-driven drug discovery and biotechnology across Asia. This transaction represents the company’s latest major operational and strategic development. This profile captures RF Acquisition Corp II's business model, main focus areas, and recent strategic changes as of late 2025.
RF Acquisition Corp II (NASDAQ:RFAI) Trading 0.3% Higher – Still a Buy?